---
title: "Insmed reports positive 12-month TPIP extension data in pulmonary arterial hypertension study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292894573.md"
description: "Insmed reported positive 12-month open-label extension data for once-daily TPIP in pulmonary arterial hypertension, supporting late-stage development. Key results included a ~55-meter increase in 6-minute walk distance and a ~60% drop in NT-proBNP. Approximately 65% of patients achieved refined low-risk status by month 12. The safety profile remained consistent with no new signals. Phase 3 PALM-PAH trial has started."
datetime: "2026-07-16T11:03:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292894573.md)
  - [en](https://longbridge.com/en/news/292894573.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292894573.md)
generator: "portal-rs"
---

# Insmed reports positive 12-month TPIP extension data in pulmonary arterial hypertension study

-   Insmed reported positive 12-month open-label extension data for once-daily TPIP in pulmonary arterial hypertension, supporting continued late-stage development. \* 6-minute walk distance rose about 55 meters from baseline in both TPIP-continued and placebo-crossed groups; NT-proBNP fell about 60%. \* About 65% of patients reached refined low-risk status on REVEAL Lite 2.0 by month 12; scores improved 2 points or 1.4 points. \* Safety profile stayed consistent through month 12 with no new signals; 7.7% discontinued; four deaths were reported, none treatment-related. \* Phase 3 PALM-PAH started; primary endpoint is change in 6-minute walk distance over 24 weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607160700PR\_NEWS\_USPR\_\_\_\_\_NY05956) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?](https://longbridge.com/en/news/297574192.md)
- [Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | INSM Stock News](https://longbridge.com/en/news/298030235.md)
- [Insmed to present at Cantor Fitzgerald global healthcare conference](https://longbridge.com/en/news/297032544.md)
- [10:16 ET/C O R R E C T I O N -- Hiperbaric/](https://longbridge.com/en/news/297531783.md)
- [Liquidia launches Phase 3 Re-Spire trial of L606 inhaled treprostinil in PH-ILD](https://longbridge.com/en/news/297786781.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**